
SOPHiA GENETICS Partners with Memorial Sloan Kettering and AstraZeneca To Broaden Access to Advanced Cancer Tests
SOPHiA GENETICS (Nasdaq: SOPH), has announced a collaboration with Memorial Sloan Kettering Cancer Center (MSK), and AstraZeneca (Nasdaq: AZN) to expand access to comprehensive cancer testing on a global scale. This strategic partnership between the three prominent organizations aims to promote global health equity by facilitating inclusive access to comprehensive cancer testing worldwide.
Cancer stands as the second leading cause of death globally, with 10 million deaths attributed to the disease in 2020, of which 70 percent occurred in low- and middle-income countries. The lack of sufficient testing, which plays a pivotal role in prevention, early detection, and advanced treatment, is a major contributor to this disparity. The collaboration will work to establish a decentralized global network for cancer testing, even in underserved regions where access to testing is currently poor.
This partnership will include SOPHiA GENETICS deploying MSK’s proprietary liquid biopsy and solid tumor cancer tests, known as MSK-ACCESS® and MSK-IMPACT®, through the technology-agnostic SOPHiA DDM™ Platform and promotion by AstraZeneca. The SOPHiA DDM™ platform employs AI to standardize, compute, and analyze digital health data, particularly in complex data modalities like genomics. The AI technology enhances the accuracy and quality of insights from multimodal datasets, enabling healthcare institutions to make data-driven decisions in various medical applications, including oncology and inherited disorders.Top of Form
Jurgi Camblong, PhD., CEO, and Co-founder of SOPHiA GENETICS emphasized the value of the decentralized SOPHiA DDM™ Platform, noting that diverse data inputs continuously enhance the platform’s artificial intelligence algorithms, thereby strengthening data outputs. The collaboration between SOPHiA GENETICS, AstraZeneca, and MSK will unlock diverse data that is vital on a global scale to revolutionize the future of cancer research and treatment.
The initial stages of this program are anticipated to be available to healthcare institutions before the close of 2023.